The 25th annual North American International Auto Show starting Monday in Detroit will feature introductions from virtually every major automaker. Some unveilings, such as the new editions of the Ford F-Series pickup and Chrysler 200 midsize sedan, are sure to command huge attention. Others will be less dramatic: refreshes or new versions of existing vehicles or niche products.
All together, they’ll also show more of the sea change underway in the auto industry. Virtually every new vehicle will be lighter and get better fuel economy than the one they replace.
Here are five key vehicles to look fo:
• Ford F-Series pickup. It would be hard to overstate the importance the new F-150 pickup. It has been nation’s best selling vehicle of any kind for the past 32 years, with 763,402 sold in 2013 alone. It also generates the lion’s share of Ford Motor profits.
Top 5 Re gional Bank Stocks To Watch Right Now: Tornier N.V.(TRNX)
Tornier N.V., a medical device company, designs, manufactures, and markets devices for joint replacement and soft tissue repair that enable surgical specialists to enhance patients? lives by restoring motion and physical vitality. It principally serves surgeons treat musculoskeletal injuries and disorders of the shoulder, elbow, hand, wrist, ankle, and foot. The company offers approximately 90 product lines, including joint replacement, trauma, sports medicine, and biologic products to treat the extremities. It also provides joint replacement products for the hip and knee in certain international markets. Tornier N.V. sells its products in approximately 35 countries worldwide. The company is headquartered in Amsterdam, the Netherlands.
- [By Seth Jayson]
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven’t materialized. Is the current inventory situation at Tornier (Nasdaq: TRNX ) out of line? To figure that out, start by comparing the company’s inventory growth to sales growth. How is Tornier doing by this quick checkup? At first glance, pretty well. Trailing-12-month revenue increased 7.3%, and inventory increased 5.8%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue increased 11.0%, and inventory grew 5.8%. Over the sequential quarterly period, the trend looks healthy. Revenue grew 4.6%, and inventory dropped 2.7%.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Tornier (Nasdaq: TRNX ) , whose recent revenue and earnings are plotted below.
Top 5 Regional Bank Stocks To Watch Right Now: ZELTIQ Aesthetics Inc (ZLTQ)
ZELTIQ Aesthetics, Inc. (ZELTIQ), incorporated on March 22, 2005, is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product is the CoolSculpting System that reduces stubborn fat bulges. The Company generates revenues from capital sales of its CoolSculpting System and from procedure fees its physician customers pay for each CoolSculpting procedure they perform. As of March 31, 2011, it had an installed base of 346 and 475 CoolSculpting Systems worldwide and over 88,000 CoolSculpting procedures had been sold to its physician customers. The Company markets CoolSculpting to the dermatologists, plastic surgeons, and aesthetic specialists. As of March 31, 2011, ZELTIQ’s North American direct sales force consisted of 23 professionals, and over 88,000 CoolSculpting procedures were sold to ZELTIQ’s physician customers.
ZELTIQ generates revenues from capital sales of its CoolSculpting System and from procedure fees its physician customers pay for each CoolSculpting procedure they perform. Capital sales of ZELTIQ’s CoolSculpting System include the CoolSculpting control unit and its CoolSculpting vacuum applicators. ZELTIQ generates procedure fees through sales of CoolSculpting procedure packs, which include its consumable gelpads and liners and a disposable computer cartridge that it markets as the CoolCard. The CoolCard contains enabling software that permits its physician customer to perform a fixed number of CoolSculpting procedures.
The CoolSculpting control unit is the base of the CoolSculpting System. ZELTIQ’s CoolSculpting control unit also contains software that tracks and collects data about each procedure performed and any error messages that may be generated during the procedure. CoolSculpting System includes three CoolSculpting vacuum applicators. ZELTIQ’s CoolSculpting procedure packs facilitate the pay-per-procedu! re feature of its CoolSculpting System. Its CoolSculpting procedure packs include CoolCard and its consumable gelpads and liners.
- [By Jake L’Ecuyer]
ZELTIQ Aesthetics (NASDAQ: ZLTQ) was also up, gaining 6.92 percent to $18.76. Stifel Nicolaus initiated coverage on the stock with a Buy rating and a $28.00 price target.
- [By Jake L’Ecuyer]
ZELTIQ Aesthetics (NASDAQ: ZLTQ) was also up, gaining 6.44 percent to $18.68. Stifel Nicolaus initiated coverage on the stock with a Buy rating and a $28.00 price target.
Top 5 Regional Bank Stocks To Watch Right Now: Actavis Inc (ACT)
Actavis, Inc., formerly Watson Pharmaceuticals, Inc., incorporated on February 1, 1985, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. The Company operates in three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. On January 23, 2013, the Company completed the acquisition of Uteron Pharma SA. On October 29, 2012, the Company sold its Rugby OTC pharmaceutical products and trademarks to The Harvard Drug Group, L.L.C. On January 24, 2012, the Company completed the acquisition of Ascent Pharmahealth Ltd.
Actavis Pharma Segment
Actavis Pharma Segment is engaged in the development, manufacturing and sale of generic, branded generic and OTC pharmaceutical products. The Company’s portfolio of generic products includes products it has developed internally and products licensed from and distributed for third parties. The Company sells its generic prescription products primarily under the Watson Laboratories, Watson Pharma and Actavis Pharma labels, and its over-the-counter generic products under private label.
Actavis Specialty Brands Segment
The Company markets a number of branded products to physicians, hospitals, and other markets that it serves. The Company classifies these trademarked products as its brand pharmaceutical products. In April 2012, it launched Gelnique 3% (oxybutynin), a clear, odorless topical gel. Gelnique 3% was obtained through an exclusive licensing agreement with Antares. The Company’s promoted products are Rapaflo, Gelnique, Trelstar, Androderm, Generess Fe and Crinone. The Company’s Actavis Specialty Brands segment also receives ot her revenues consisting of co-promotion revenue and royaltie! s.
Anda Distribution Segment
The Company Anda Distribution business primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables and over-the-counter medicines to independent pharmacies, alternate care providers (hospitals, nursing homes and mail order pharmacies), pharmacy chains and physicians’ offices. In addition, it sells to members of buying groups, which are independent pharmacies that join together to enhance their buying power. As of December 31, 2012, the Company distributes products from its facilities in Weston, Florida, Groveport, Ohio, and Olive Branch, Mississippi, as well as a small volume of product from Puerto Rico.
The Company competes with Teva Pharmaceutical Industries, Ltd., Mylan Inc., Sandoz, Inc, McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc.,
- [By Holly LaFon]
The Fund’s average overweight position (20% versus 13%) and holdings in the Health Care sector (up 8% compared to up 6% for the S&P 500 sector) contributed to results. Forest Laboratories (FRX) (up 54%) agreed to be acquired by Actavis PLC (ACT). Merck (up 14%) also performed well.
- [By Dan Burrows]
True, that’s peanuts compared to the $100 billion Pfizer (PFE) is offering for AstraZeneca (AZN), and just a fraction of the $46 billion Valeant (VRX) offered for Allergan (AGN). Holders of Merck stock probably know the deal between MRK and Bayer even pales compared to the $25 billion acquisition of Forest Labs (FRX) by Actavis (ACT).
- [By Lauren Pollock]
Actavis(ACT) PLC confirmed plans to acquire rival drug maker Forest Labs in a cash-and-stock deal that values Forest at about $25 billion. Shares of Forest Labs rose 30% to $93.06 premarket. Actavis shares rose 8.2% to $207.70.
- [By Jake L’Ecuyer]
Equities Trading UP
Forest Laboratories (NYSE: FRX) shot up 29.85 percent to $92.70 after Actavis (NYSE: ACT) announced its plans to buy Forest Labs for $25 billion. Analysts at Morgan Stanley upgraded Forest Labs from Equal-Weight to Overweight.
Top 5 Regional Bank Stocks To Watch Right Now: Osiris Therapeutics Inc.(OSIR)
Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. It operates in two business segments, Therapeutics and Biosurgery. The Therapeutics segment focuses on developing biologic stem cell drug candidates from a readily available and non-controversial source, adult bone marrow. The Biosurgery segment works to harness the ability of cells and novel constructs to promote the body’s natural healing. This segment focuses on developing biologic products for use in surgical procedures. The company?s lead biologic drug candidate is Prochymal, which is in phase 2 and 3 clinical trails for various indications, including acute graft versus host disease (GvHD), Crohn’s disease, acute myocardial infarction, type 1 diabetes, pulmonary disease, and gastrointestinal injury resulting from radiation exposure. Its biologic drug c andidates also include Chondrogen, a preparation of adult mesenchymal stem cells that is in phase 2 clinical trials for osteoarthritis and cartilage protection. The company has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen in various countries except in the United States and Canada. It also has a partnership with Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
- [By Lauren Pollock]
Osiris Therapeutics Inc.(OSIR) said Friday a proposed ruling from the Centers for Medicare and Medicaid Services won’t immediately affect reimbursements for its Grafix stem-cell product. The regenerative medicine company said Grafix will maintain its current reimbursement status — also called transitional pass-through status — potentially through late 2015.
- [By Maxx Chatsko]
Additionally, stem cell therapies have remained elusive as the industry’s ultimate Holy Grail. Osiris (NASDAQ: OSIR ) received Canadian approval for the world’s first stem cell drug, Prochymal, for children battling acute graft-versus-host disease, or GvHD, last year. The approval meant more symbolically than to the bottom line, but it definitely put the potential of stem cells front and center for investors.
Top 5 Regional Bank Stocks To Watch Right Now: Hess Corporation (HES)
Hess Corporation, together with its subsidiaries, operates as an independent energy company worldwide. It operates in two segments, Exploration and Production (E&P), and Marketing and Refining (M&R). The E&P segment explores for, develops, produces, purchases, transports, and sells crude oil and natural gas. This segment conducts exploration and production activities principally in Algeria, Australia, Azerbaijan, Brunei, China, Denmark, Egypt, Equatorial Guinea, France, Ghana, Indonesia, the Kurdistan region of Iraq, Libya, Malaysia, Norway, Peru, the Russian Federation, Thailand, the United Kingdom, and the United States. The M&R segment purchases, markets, and trades in refined petroleum products, natural gas, and electricity. This segment serves motoring public, wholesale distributors, industrial and commercial users, other petroleum companies, governmental agencies, and public utilities. It also operates terminals and retail gasoline stations, which include convenience stores located on the East Coast of the United States. As of December 31, 2012, the company operated 1,361 HESS gasoline stations in New York, New Jersey, Pennsylvania, Florida, Massachusetts, North Carolina, and South Carolina. Hess Corporation was founded in 1920 and is headquartered in New York, New York.
- [By Matt DiLallo]
That being said, this is a man who has already completed three Utica Shale deals this year. He spent $924 million to buy the 74,000 Utica Shale acres that Hess (NYSE: HES ) sold earlier this year. On top of that, he completed a deal with ExxonMobil’s (NYSE: XOM ) XTO Energy unit to fund 100% of the near-term drilling costs of 55,000 net acres in a “core area” of the Utica Shale. In return, McClendon’s company will receive ownership of 30,000 net acres from ExxonMobil in the Utica Shale. A third deal brought the company’s total haul in the Utica Shale up to 130,000 net acres, which doubled its holdings in the region.
- [By Matt DiLallo]
Chesapeake Energy’s advantage
Chesapeake Energy already has a long history in the Utica Shale. It was the first company to turn a well into production in June of 2011. The competition didn’t start putting wells online until nearly a year later when Hess (NYSE: HES ) brought its first well into production that April. Being first in the basin is proving to be a real competitive advantage for Chesapeake Energy as it has drilled more wells than all of its competitors combined as the following slide shows.